AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00566696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-phenylalanine mustard
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Study NCT00566696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Study NCT00566696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan™
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Study NCT00566696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.
Study NCT00566696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Study NCT00566696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (Rabbit)
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Study NCT00566696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Study NCT00566696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muromonab
Description: Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
Study NCT03553303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet
Description: Increasing doses of Sacubitril/Valsartan
Study NCT02143388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMRT combine with cisplatin concurrent chemotherapy
Description: Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.
Study NCT02143388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
Description: Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
Study NCT02321709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR113244
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study NCT02321709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study NCT03369262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE022
Description: Oral
Study NCT03369262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Oral
Study NCT03369262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: I.V.
Study NCT03369262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atosiban
Description: I.V.
Study NCT04859933 — intervention group
Intervention type: PROCEDURE
Intervention: AV-node isolation
Description: Abaltion performed in the right atrium isolating the AV-node from the atrium
Study NCT04859933 — intervention group
Intervention type: PROCEDURE
Intervention: AV-node ablation
Description: Right sided ablation of the AV-node
Study NCT01847027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NutraStem
Description: Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.~Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
Study NCT01847027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
Study NCT00773214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12-week supervised exercise programme (5 times /week at 75% maximal Heart Rate)
Study NCT00611026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine ER
Description: The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
Study NCT00611026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment will be once daily(QD) for 12 weeks.
Study NCT00611026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
Study NCT04338802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 MG
Description: Nintedanib cloth sulfonate 150 mg, twice a day, about 12 hours apart. Continuous medication for 8 weeks.
Study NCT04338802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empty capsules with the same appearance and ingredients as Nidanib soft capsules: one capsule at a time, twice a day, with an interval of about 12 hours each time. Continuous medication for 8 weeks.
Study NCT01310075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alloderm
Description: 6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
Study NCT01310075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgimend
Description: 10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
Study NCT03154411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-029
Description: A minimum of 6 and a maximum of 12 adult patients with a diagnosis of primary soft-tissue sarcoma will be enrolled. Initial diagnostic biopsy specimens will be analyzed for EGFR positivity (an EGFR pathology score ≥ 1) by immunohistochemistry following routine diagnostic processing by Pathologist. Patients will be administered a single intravenous dose of ABY-029 1-3 hours before surgery.
Study NCT04724109 — intervention group
Intervention type: DRUG
Intervention: Equfina
Description: Equfina oral tablets.
Study NCT04240548 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Regional Nodal Irradiation
Study NCT02502617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: medical nutrition
Description: The participants are expected to improve their body weight with 10-30% during a closely monitored inpatient-treatment comprising nutritional rehabilitation.
Study NCT01879098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic: Bacillus subtilis
Description: Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
Study NCT01879098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Description: Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
Study NCT01879098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis
Description: Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
Study NCT01879098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
Study NCT00467753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
Study NCT00467753 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/sugar pill
Description: Dosage similar to active drug
Study NCT02185482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Supported Care
Study NCT02185482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study NCT04436848 — intervention group
Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study
Study NCT01583296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Relaxation Therapy (MRT)
Description: music relaxation therapy and breathing at resting respiration rate
Study NCT01583296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT and HRVB
Description: cognitive behavioral therapy and heart rate variability biofeedback
Study NCT02111304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iOWH032
Study NCT03929497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167
Description: Lu AF11167 - 2 or 4 mg/day; tablets, orally
Study NCT02106858 — intervention group
Intervention type: DRUG
Intervention: Regorafenib (Stivarga,BAY73-4506)
Description: Patients treated by Physician with Stivarga under approved local prescriptions
Study NCT00267566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strongest Families (formerly Family Help Program): Anxiety Program
Description: Evidence-based psychological and behavioural distance intervention
Study NCT03612752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CMI-168
Description: Dietary supplement
Study NCT03612752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03117140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75%
Description: Only ropivacaine 0.75% is administered for this arm of the interscalene block
Study NCT03117140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% + 300 mcg Buprenorphine
Description: Ropivacaine 0.75% + 300 mcg Buprenorphine is administered for this arm of the interscalene block
Study NCT03117140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% + 75 mcg clonidine
Description: Ropivacaine 0.75% + 75 mcg Clonidine is administered for this arm of the interscalene block
Study NCT03117140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% + 8 mg dexamethasone
Description: Ropivacaine 0.75% + 8 mg Dexamethasone is administered for this arm of the interscalene block
Study NCT03186742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg Tab
Description: Eplerenone 50 mg Tab once a day
Study NCT02533453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bydureon
Description: exenatide once weekly
Study NCT04041167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha lipoic acid
Description: alpha lipoic acid treatment
Study NCT04041167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: No alpha lipoic acid treatment
Study NCT01732237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42396302
Description: A single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
Study NCT01732237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42692507
Description: A single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
Study NCT01732237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53773187
Description: A single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
Study NCT02512029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-1451
Study NCT03599219 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: sample
Description: confirmation of platelet dysfunction
Study NCT01075542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof Toric intraocular lens, model SN60TT
Description: The lens is made of foldable acrylic material and is implanted in the capsular bag
Study NCT01075542 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AcrySof Monofocal IOL, model SN60AT
Description: The lens is made of foldable acrylic material and is implanted in the capsular bag
Study NCT01626872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 3mg
Description: In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
Study NCT01626872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 6mg
Description: In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
Study NCT01626872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 9mg
Description: In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
Study NCT01626872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone 4mg
Description: In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
Study NCT02998268 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study NCT02998268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study NCT02998268 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Taxol
Description: Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
Study NCT02998268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
Study NCT02998268 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
Study NCT02998268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
Study NCT02451709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activated Smartinhaler or Smartturbo
Description: Medication reminder alarms
Study NCT02451709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback of adherence data
Description: Review of adherence data with action planning
Study NCT02451709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deactivated Smartinhaler or Smartturbo
Description: Alarms deactivated and no feedback
Study NCT00574522 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Far infrared
Description: Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
Study NCT01033799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)
Study NCT01033799 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non fermented dairy product (control)
Study NCT03881527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement using a nitinol blade
Description: A circular nitinol blade will be inserted by to cut the aortic valve leaflets during conventional aortic valve replacement procedure
Study NCT03881527 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: aortic valve replacement
Description: Aortic valve replacement in a standard fashion
Study NCT02598583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1210
Description: Participants were administered ravulizumab as an IV infusion every 4 weeks.
Study NCT01578876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiac shock wave therapy(CSWT)
Description: CSWT was performed with the MODULITH SLC SW therapy device (Storz Medical, Switzerland).Shock waves were triggered by the R-wave of the ECG when the instrument was activated. The shock wave energy was increased from an initial low level up 0.09 mJ/mm2 if the patient experienced no discomfort such as chest pain. Point-to-point combination treatment for the ischemic areas with 200 pulses delivered to each point was given.
Study NCT03172416 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: This study started as a prospective, single arm phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC using oxaliplatin in patients with peritoneal carcinomatosis.
Study NCT03172416 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin & Nivolumab
Description: PIPAC oxaliplatin 90mg/m2 has been well tolerated in our Cohort 1 study. Hence, we added a second cohort (Cohort 2) which combines PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks to evaluate the safety and tolerability of combination therapy.
Study NCT01915069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Study NCT00946283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: Culturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water
Study NCT00728403 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American Ginseng (Panax quinquefolius L.) and Korean Red Ginseng (steamed Panax C.A. Meyer)
Description: 1.5 grams American Ginseng and 1.5 grams Korean Red Ginseng are to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
Study NCT00728403 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American Ginseng (Panax quinquefolius L.)
Description: 3 grams of American Ginseng is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
Study NCT00728403 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Bran
Description: 3 grams of Wheat Bran is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
Study NCT03810105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300mg twice daily (600mg total daily dose)